Liposomal Amikacin Market to 2028, Future Outlook, COVID-19 Impact Analysis, Forecast -2028

The global liposomal amikacin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). As drugs, liposomes offer several advantages including biocompatibility, capacity for self-assembly, ability to carry large drugs payloads, and a wide range of physicochemical and biophysical properties that can be modified to control their biological characteristics. Amikacin liposomal is used to treat adults with refractory which is difficult to treat Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug treatment plan (Regimen). This medical is an aminoglycoside antibiotic. This medicine is sold only when prescribed by the doctor. Amikacin liposome inhaled suspension (ALIS) can deliver amikacin to the infected site effectively and reduce systemic toxicity.

(Get 15% Discount on Buying this Report)
A full report of Global Liposomal Amikacin Market is available at: https://orionmarketreports.com/liposomal-amikacin-market/96025/

Some major players in the market include Insmed Inc., and Cipla Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2019 Luye Pharma Group an innovative paclitaxel liposome formulation was included and approved as a first-line drug for non-squamous cell carcinoma in the Chinese Society of Clinical Oncology (CSCO) Guidelines.

In September 2018, Insmed Inc. declared that the US Food and Drug Administration (FDA) has granted accelerated approval of ARIKAYCE (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. ARIKAYCE is the first therapy approved in the US specifically for patients with MAC lung disease, a chronic and debilitating condition that can significantly increase patient morbidity and mortality.

Market Coverage
• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Distribution Channel

• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World

Competitive Landscape- Insmed Inc., and Cipla Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?

Global Liposomal Amikacin Market Report by Segment

By Type
• Branded
• Generic

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.